Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer

Bristol Myers Squibb's 4.1% dividend yield is sustainable in the near term, with earnings and free cash flow covering the payout more than twice over. However, the company faces a significant patent cliff as key drugs like Eliquis and Opdivo lose exclusivity by 2028, threatening roughly half of total revenue. While the dividend appears safe for now, investors should monitor how management navigates these challenges, potentially through slower dividend growth.